Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.66 |
| ▸ | CCR7 | P32248 | 5/20 | 0.43 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.42 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3854052 | 0.89 | CXCR2 (0.54) | CXCR2CX3CR1 | |
| SCHEMBL6343828 | 0.88 | CXCR2 (0.67) | CXCR2CCR7CX3CR1 | |
| SCHEMBL3860775 | 0.87 | CXCR2 (0.66) | CXCR2CCR7 | |
| SCHEMBL3858985 | 0.85 | CXCR2 (0.83) | CXCR2CCR7CX3CR1 | |
| SCHEMBL3853004 | 0.83 | CXCR2 (0.72) | CXCR2CCR7CX3CR1 | |
| SCHEMBL3857942 | 0.82 | CXCR2 (0.68) | CXCR2CCR7CX3CR1 | |
| SCHEMBL3851449 | 0.82 | CXCR2 (0.73) | CXCR2CCR7CX3CR1 | |
| SCHEMBL3861396 | 0.82 | CXCR2 (0.52) | CXCR2CX3CR1 | |
| SCHEMBL3854713 | 0.81 | CXCR2 (0.72) | CXCR2CCR7CX3CR1CXCR1 | |
| SCHEMBL3857366 | 0.81 | CXCR2 (0.64) | CXCR2CCR7CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579342-B2 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA (SE) | 2009-08-25 | — | — | US | disclosed |
| EP-1419158-B1 | PTERIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-08-01 | — | — | EP | disclosed |
| US-20070142352-A1 | Pteridinone Derivatives as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20060111569-A1 | Thiazolopyrimidines and their use as modulators of chemokine receptor activity | BONNERT ROGER | 2006-05-25 | — | — | US | disclosed |
| US-6949643-B2 | Thiazolopytimidines and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2005-09-27 | — | — | US | disclosed |
| US-20050171345-A1 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| US-6875868-B2 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB (SE) | 2005-04-05 | — | — | US | disclosed |
| EP-1385854-B1 | THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2005-02-09 | — | — | EP | disclosed |
| US-20050010047-A1 | Pteridinone derivatives as modulators of chemokine receptor activity | BONNERT ROGER VICTOR (GB) | 2005-01-13 | — | — | US | disclosed |
| US-20040157853-A1 | Thiazolopytimidines and their use as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-08-12 | — | — | US | disclosed |
| EP-1419158-A1 | PTERIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Astrazeneca AB (SE) | 2004-05-19 | — | — | EP | disclosed |
| EP-1385854-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1259512-B1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003024966-A1 | PTERIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-27 | — | — | WO | disclosed |
| US-20030055250-A1 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| EP-1259512-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002083693-A1 | THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2001062758-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111569-A1 | Thiazolopyrimidines and their use as modulators of chemokine receptor activity | CXCR2, CCR5, CXCR1 | CXCR2 1/4885CCR7 16/4885CX3CR1 13/4885 |
| US-20050010047-A1 | Pteridinone derivatives as modulators of chemokine receptor activity | CCR5, CXCR3, CCR2 | CXCR2 11/4885CCR7 6/4885CX3CR1 8/4885 |
| US-20040157853-A1 | Thiazolopytimidines and their use as modulators of chemokine receptor activity | CCR5, CCR2, CX3CR1 | CXCR2 5/4885CCR7 17/4885CX3CR1 3/4885 |
| US-20030055250-A1 | Pteridine compounds for the treatment of psoriasis | DHFR, NAMPT, HPRT1 | CXCR2 1307/4885CCR7 369/4885CX3CR1 1991/4885 |
| US-20070142352-A1 | Pteridinone Derivatives as Modulators of Chemokine Receptor Activity | CCR5, CXCR3, CCR2 | CXCR2 11/4885CCR7 6/4885CX3CR1 8/4885 |
| US-20050171345-A1 | Pteridine compounds for the treatment of psoriasis | DHFR, NAMPT, HPRT1 | CXCR2 1307/4885CCR7 369/4885CX3CR1 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.